Celecoxib plus standard chemo for CD5+ DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with CD5-positive diffuse large B-cell lymphoma (a specific subtype of a common lymphoma) and have not received any treatment for it yet.
- Your lymphoma is stage III or IV (advanced) and you have at least one tumor that can be measured on scans.
- You are in generally good health (able to care for yourself) and your heart, liver, kidney, and blood cell counts are within acceptable ranges.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (TRS005) combined with standard chemotherapy (cyclophosphamide, doxorubicin, and prednisone) as a first treatment for people with CD20-positive DLBCL. The goal is to see if this combination is safe and effective in controlling the lymphoma.
This study tests whether using a special blood test (ctDNA) to guide targeted therapy can improve outcomes for people with a type of lymphoma called DLBCL. If you qualify, you may receive a standard chemo-immunotherapy regimen (R-CHOP) possibly combined with other drugs, and your treatment plan may be adjusted based on your ctDNA levels.
This trial tests whether adding a new targeted drug called birelentinib to the standard chemotherapy combination (R-CHOP) helps people with newly diagnosed aggressive lymphoma. It aims to improve the chances of remission and reduce the risk of the lymphoma coming back.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
This trial compares two treatments for a certain type of aggressive lymphoma: the standard R-CHOP chemotherapy plus a study drug called tucidinostat (which may help fight cancer cells). The aim is to see if adding this drug helps patients with the double-expressor subtype do better.
This study tests whether adding a drug called trilaciclib to standard chemotherapy can help people with newly diagnosed Diffuse Large B-Cell Lymphoma. It aims to see if this combination keeps blood counts healthier and improves treatment outcomes.
Hear when a new Diffuse Large B-Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.